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Abstract
Background:  Previous studies found that rats subjected to carrageenan injection develop
hyperalgesia, and despite complete recovery in several days, they continue to have an enhanced
hyperalgesic response to a new noxious challenge for more than 28d. The study's aim was to
identify candidate genes that have a role in the formation of the long-term hyperalgesia-related
imprint in the spinal cord. This objective was undertaken with the understanding that the long-
lasting imprint of acute pain in the central nervous system may contribute to the transition of acute
pain to chronicity.
Results:  To analyze changes in gene expression when carrageenan-induced hyperalgesia has
disappeared but propensity for the enhanced hyperalgesic response is still present, we determined
the gene expression profile using oligo microarray in the lumbar part of the spinal cord in three
groups of rats: 28d after carrageenan injection, 24h after injection (the peak of inflammation), and
with no injection (control group). Out of 17,000 annotated genes, 356 were found to be
differentially expressed compared with the control group at 28d, and 329 at 24h after carrageenan
injection (both groups at p < 0.01). Among differentially expressed genes, 67 (39 in 28d group)
were identified as being part of pain-related pathways, altered in different models of pain, or
interacting with proteins involved in pain-related pathways. Using gene ontology (GO)
classification, we have identified 3 functional classes deserving attention for possible association
with pain memory: They are related to cell-to-cell interaction, synaptogenesis, and neurogenesis.
Conclusion: Despite recovery from inflammatory hyperalgesia, persistent changes in spinal cord
gene expression may underlie the propensity for the enhanced hyperalgesic response. We suggest
that lasting changes in expression of genes involved in the formation of new synapses and
neurogenesis may contribute to the transition of acute pain to chronicity.
Background
Pain that persists well beyond the healing of the injury,
including surgical wounds, is a major clinical problem
[1]. Multiple mechanisms are likely responsible for per-
Published: 13 March 2008
BMC Neuroscience 2008, 9:32 doi:10.1186/1471-2202-9-32
Received: 6 August 2007
Accepted: 13 March 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/32
© 2008 Yukhananov and Kissin; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
Page 2 of 14
(page number not for citation purposes)
sistent postinjury pain; some may be related to the transi-
tion of acute pain to chronicity, a concept that is
supported by reports of the relationship between the
intensity of acute postoperative pain and subsequent
development of chronic pain after surgery [2-4]. A long-
lasting imprint of acute pain may contribute to its transi-
tion to chronic pain. In the rat model, acute pain and
hyperalgesia following an inflammation disappeared
within a few days, but enhanced sensitivity to a new nox-
ious challenge (inflammation) may persist for a very long
time [5,6]. Our previous experiments with repeated injec-
tions of carrageenan into the hindpaws demonstrated
that, well after recovery (2 to 4 weeks later) from hyperal-
gesia induced by the initial inflammation, repeated-cross-
over carrageenan injection causes a distant (in
contralateral hindpaw) hyperalgesia that was absent after
the initial injection. The acute pain and hyperalgesia fol-
lowing an injection of carrageenan disappears within a
few days, but despite recovery the enhanced response to a
new noxious challenge may persist for a very long time
[5,7]. This phenomenon was viewed as an indication of
the long-lasting imprint of acute pain in the CNS [7].
It seems plausible that the transition to chronic pain
involved modification of gene expression within the spi-
nal cord, which might be a mechanism of long-term
imprinting of pain hypersensitivity. However, the picture
of gene expression alterations and their role in control of
acute and chronic pain is far from clear [8-10]. Multiple
pathways seems to be involved, and their elucidation will
require global profile studies of gene expression using dif-
ferent models of acute and chronic pain with and without
drug intervention. We have found no studies on changes
in gene expression long after recovery from inflammatory
hyperalgesia. The aim of this study was to characterize
changes in gene expression when animals are long recov-
ered from hyperalgesia but have maintained a propensity
for enhanced hyperalgesic response. We hypothesized
that following the recovery from inflammatory hyperalge-
sia there were persistent changes in spinal cord gene
expression.
Results
Carrageenan injection into a rat's hind paw induces
inflammation and hyperalgesia (Fig. 1). Inflammation
measured as increased paw volume reaches its maximum
3–24h after injection. The differences in paw volume
between the injected and contralateral paws are minimal
after 5 days and completely disappear in 2 weeks (Fig. 1B).
Injection-induced hyperalgesia disappears at 24h (Fig.
1A). However, as was shown in previous experiments,
after recovery from hyperalgesia a repeated-crossover
injection of carrageenan (in the opposite hindpaw) pro-
duced a more exaggerated response, resulting in profound
distant hyperalgesia in the originally injected paw even
28d later [7]. In order to distinguish the acute changes
Effect of carrageenan on noxious pressure threshold and paw volume Figure 1
Effect of carrageenan on noxious pressure threshold and paw volume. The carrageenan was injected in the plantar 
surface of the right paw (2%, 0.1 ml). Left Graph. Noxious pressure threshold was measured by Analgesia-Meter (Ugo Basile). 
Right Graph. Volume measured by a plethysmometer. Data expressed as mean ± SD. The threshold to noxious pressure in the 
right hindpaw, decreased after carrageenan injection, recovered the next day and was equal to the threshold in the left hind-
paw for the whole period of observation (up to 28d).
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induced by inflammation from long-term changes related
to pain memory, we collected tissue samples both at 24h
following injection, when the inflammation is still signif-
icant but there is no hyperalgesia, and at 28d, when as
reported previously [7] there is no inflammation but
enhanced response to pain stimulus, or "pain memory."
The statistical analysis of gene expression data is still a
challenge. There is no standard approach to select differ-
entially expressed genes. Often the combination of p-val-
ues and fold differences is used to select "interesting"
genes for further analysis [10]. However, to use fold
changes for the central nervous system is not efficient,
since the changes in gene expression are small and diluted
by the large variety of unaffected neurons. In addition,
fold changes are not statistically validated metrics and in
many cases produce spurious results [11]. In this study,
we used the Rosetta Resolver statistical model and based
our analysis only on p-value. We compared the number of
differentially expressed genes at different p-values. For fur-
ther analysis, we have used p < 0.01 as a cutoff. It was
shown that selecting genes based on p < 0.01 results in
more than 80% confirmation rate by real-time PCR [12]
and provides a reasonable compromise between strin-
gency and exploratory value of the analysis (Table 1).
Using this method we have identified 629 differentially
expressed genes in the 28d group and 512 genes in the
24h group out of a total of 31,042 reliably measured tran-
scripts (see Additional file 1). These numbers include
both annotated and uncharacterized genes (EST). Further
analysis was limited to 356 full-length annotated genes
that were differentially expressed compared with the con-
trol group at 28d after injection and 329 full-length anno-
tated genes that were differentially expressed compared
with the control group at 24h after injection (see Addi-
tional file 1). The low variability of our data permitted us
to detect highly significant differences with relative
changes as low as 10%.
In the next step we have characterized the functional
groups based on gene ontology (GO) classification using
DAVID tools (Table 2 and 3). There are several groups
overrepresented only at 24h, when inflammatory
response is near its peak (Table 2): protein synthesis/
ribosomal protein group and proteins involved in the
immune response. Chaperones involved in protein fold-
ing were also overrepresented at 24h but with smaller
probability. The different groups were overrepresented at
28d (Table 3), such as the genes involved in cell-to-cell
interaction, cell proliferation and neurogenesis, morpho-
genesis, and neuron differentiation–in other words,
involved in the formation of new synapses and neurogen-
esis. DAVID-based GO analysis showed that genes respon-
sible for regulation of apoptosis, phosphorylation, and
acetylation were also overrepresented only at 28d group
(Table 3). Several functional groups related to regulatory
pathways were overrepresented both at 24h and 28d, for
example, proteins responsible for ion binding (Table 2
and 3) but it may reflect their overrepresentation in neu-
rons since we have used Affy chip as background for anal-
ysis (see Methods). Using SOM, we have grouped the
known differentially expressed genes into eight clusters
(Fig. 2). Clusters A and B contain the majority of selected
genes (n = 233). Cluster A (n = 122) includes genes that
increased at 24h after injection and then increased even
further at 28d, whereas genes belonging to cluster B (n =
111) changed in the opposite direction: They decreased at
24h and further decreased at 28d. Clusters C and D are
similar and include 51 genes that are practically not
altered 24h after injection but then slightly increased
(cluster C) or slightly decreased (cluster D) at 28d. Genes
(n = 177) belonging to clusters E and H increased at 24h
(cluster E) or decreased (cluster H) and remained at the
same level up to 28d after injection. The last two clusters
(G and F) include genes that increased (F) or decreased
(G) at 24h and returned to the control level at 28d.
In order to see whether clusters G and F reflect changes in
gene expression related to ongoing inflammation, we
have selected the group (n = 16) of known mediators of
inflammation. They have a similar profile with maximal
changes at 24h following injection and practically
expressed at the same level as the control group 28d fol-
lowing injection (Fig. 3).
As indirect validation of our result, among differentially
expressed genes in both groups we identified (see meth-
ods) 67 genes (39 in the 28d group) previously reported
to be involved in pain-related pathways, altered in differ-
ent models of pain, or interacting with protein involved in
pain. These genes were divided into several functional
groups (Table 4). The first group includes membrane
receptors and their ligands. The second contains ion chan-
nels, regulators of ion homeostasis, and calcium sensors
(e.g., calmodulin) (Table 3). We selected 2 groups that
contain signal transduction molecules: the MAPK path-
way and proteins involved in cAMP signaling. The fifth
group consists of growth factors known to modify pain
sensitivity: BDNF [13] and its receptor (NtrkB),
neuregulin1, and IGF binding proteins. The sixth group
Table 1: The number of probe set selected according to p-value.
p-value 28d vs control 24h vs control
All 31042 31042
<0.05 1781 1560
<0.01 629 512
<0.005 441 358
<0.001 177 167BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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includes critical components of the arachidonic acid (AA)
cascade, a known mediator of inflammatory pain.
Several genes ("Others", group 7) did not fit in any of
these groups. Gene expression of this group (Table 4) has
been reported to be altered in different pain models.
Annexin 3 level was increased during episodes of migraine
[14]; microtubule-associated protein 1B was altered 7
days after chronic constriction injury (CCI) [15]; synap-
toporin, a major synaptic vesicle protein in Adelta- and C-
fibers and co-localized with calcitonin gene-related pep-
tide (CGRP) in sensory primary afferent neurons,
increased after peripheral nerve injury [16].
Table 2: Ontologic classification of genes differentially expressed at 24h and 28d (B).
Category Number of sequences % of total p-value
Protein synthesis/ribosome
ribosome 18 5.20% 6.10E-12
protein biosynthesis 19 5.50% 3.60E-10
ribonucleoprotein complex 25 7.30% 1.80E-08
eukaryotic 43S preinitiation complex 7 2.00% 1.60E-05
eukaryotic 48S initiation complex 6 1.70% 6.00E-05
Protein folding
posttranslational protein folding 4 1.20% 2.40E-03
chaperone cofactor dependent protein folding 4 1.20% 1.40E-03
response to unfolded protein 6 1.70% 2.70E-03
Immune response
immunoglobulin domain 16 4.70% 4.90E-05
A-macroglobulin receptor 3 0.90% 1.20E-02
Regulatory pathway
response to stress 34 9.90% 5.50E-03
signal transduction inhibitor 4 1.20% 6.90E-03
cation binding 44 12.80% 3.60E-03
calmodulin binding 6 1.70% 7.50E-03
Functional analysis of differentially expressed transcript employed DAVID tools (see Methods for detailed description). To calculate background, 
Affychip has been used. Some transcripts represent in more than one category. Cutoff value for category selection p < 0.05.
Table 3: Ontologic classification of genes differentially expressed at 28d.
Category Number of sequences % of total p-value
Cadherin-like 13 3.40% 1.30E-14
cell-cell adhesion 18 4.70% 4.10E-07
Synapse formation
regulation of cell proliferation 20 5.20% 5.70E-04
neurogenesis 15 3.90% 7.60E-03
morphogenesis 34 8.90% 2.70E-03
neuron differentiation 15 3.90% 2.80E-03
Apoptosis
regulation of apoptosis 22 5.80% 1.80E-04
negative regulation of apoptosis 12 3.10% 8.90E-04
Regulatory pathways
calcium ion binding 31 8.10% 2.60E-06
ion binding 62 16.30% 5.50E-04
transmission of nerve impulse 20 5.20% 4.90E-04
actin polymerization and/or depolymerization 7 1.80% 2.40E-04
cytoskeleton organization and biogenesis 18 4.70% 1.70E-03
nerve ensheathment 5 1.30% 4.30E-03
Enzyme
phosphorylation 39 10.20% 9.50E-04
acetylation 14 3.70% 3.20E-03
Functional analysis of differentially expressed transcript employed DAVID tools (see Methods for detailed description). To calculate background, 
Affychip has been used. Some transcripts represent in more than one category. Cutoff value for category selection p < 0.05.BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
Page 5 of 14
(page number not for citation purposes)
Several genes were included in group 7 based on indirect
evidence of their involvement in pain regulation. Tubulin
isoform beta5 interacts with vanilloid receptor (TRPV1)
and is probably a downstream effector of TRPV1 activa-
tion [17]. Chaperonin subunit 4 (cct4) involved in fold-
ing tubulin and other cytosolic proteins is included, since
mutation of this protein leads to early onset sensory neu-
ropathy [18]. Fyn proto-oncogene phosphorylates NMDA
receptors in response to pain stimuli [19].
In order to verify the microarray result by independent
methods, we randomly selected six of the differentially
expressed genes and two non-differentially expressed
genes to measure their expression by qPCR (Fig. 4). We
found significant (p < 0.001) correlation between expres-
sion value obtained using microarray and the real-time
PCR results at 28d following carrageenan injection.
Clustering of genes differentially expressed at 24h and 28d Figure 2
Clustering of genes differentially expressed at 24h and 28d. Data presented as mean ± SEM. Genes were classified by 
SOM; n = number of genes in each cluster. * – p < 0.001 compared to control, #- p < 0.001 compared to 24h group.
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Discussion
The acute pain following a single injection of carrageenan
disappears within a few days; however, the enhanced sen-
sitivity to a new noxious challenge may persist for a pro-
longed time [5-7]. The enhanced sensitivity may
contribute to posttraumatic and postsurgical persistent
pain. In experiments with repeated carrageenan injections
in response to the first injection into a rat's hind paw, the
induced hyperalgesia was profound on the side of injec-
tion and minimal or absent in the contralateral hind paw.
However, repeated injection of carrageenan into the pre-
viously noninjected hind paw resulted in pronounced
hyperalgesia in the other paw. The difference between dis-
tant hyperalgesia after the initial and repeated-crossover
injection of carrageenan was used as a measure of the
Profile of gene expression for inflammation-related genes Figure 3
Profile of gene expression for inflammation-related genes. The selected inflammation-related genes were clustered 
with SOM. Data presented as mean ± SEM.
Name Affymetrix GenBank Description
Cxcl9 1373544_at NM_145672 chemokine ligand 9
Csf1r 1388784_at NM_001029901 Macrophage colony stimulating factor I receptor
Il10 1387711_at NM_012854 interleukin 10
Il2rb 1387394_at NM_013195 interleukin 2 receptor  beta chain
Il6ra 1386987_at NM_017020 interleukin 6 receptor, alpha
Il13ra1 1388711_at NM_145789 interleukin 13 receptor, alpha 1
Il1r2 1387180_at NM_053953 interleukin 1 receptor  type II
Tnfrsf4 1387621_at NM_013049 tumor necrosis factor receptor superfamily  member 4
Tnfrsf1a 1367715_at NM_013091 tumor necrosis factor receptor superfamily, member 1a
Il18 1369665_a_at NM_019165 interleukin 18
Litaf 1370928_at BI284739 LPS-induced TNF-alpha factor
Il6st 1383489_at NM_001008725 interleukin 6 signal transducer
Ccl17 1370118_at NM_057151 small inducible cytokine subfamily A (Cys-Cys)  member 17
Tnfsf13 1377353_a_at NM_001009623 TNF superfamily member 13
Ccl7 1379935_at NM_001007612 chemokine ligand 7
Il24 1368210_at NM_133311 interleukin 24
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Table 4: Genes differentially expressed 24h or 28d following carrageenan injection and known to be involved in pain.
GenBank Description Name P-value Cluster Selection criteria References
1. Membrane receptors and their ligands
NM_022225 5-hydroxytryptamine (serotonin) receptor 1b Htr1b 0.0005 A w [48]; [49]
NM_012685 vasoactive intestinal peptide receptor 1 Vipr1 0.0017 A w [50]
U30290 galanin receptor 1 Galr1 0.0095 B w [51]
BI395810 neuropeptide y receptor y1 Npy1r 0.0085 B w [52]
NM_017155 adenosine a1 receptor Adora1 0.0034 E w [53]
U28430 5-hydroxytryptamine (serotonin) receptor 3a Htr3a 0.0002 E w [48]
NM_022695 neurotensin receptor 2 Ntsr2 0.0001 E w [54]
BF412731 prodynorphin Pdyn 0.0000 F w, z [55]
M11596 calcitonin-related polypeptide, beta Calcb 0.0000 G w, z [56]
BG376217 glutamate receptor, ionotropic, ampa1 (alpha 1) Gria1 0.0073 H w [57]
NM_017011 glutamate receptor, metabotropic 1 Grm1 0.0000 H w [37]
NM_012870 neuropeptide y receptor y5 Npy5r 0.0021 H w, z [32]; [58]
2. Ion channels and regulator of ion homeostasis
AI010839 potassium large conductance calcium-activated channel, 
subfamily m, alpha member 1
Kcnma1 0.0050 A w [59]
M34052 potassium voltage gated channel, shaw-related subfamily, 
member 2
Kcnc2 0.0014 B w [59]
AI717104 potassium inwardly-rectifying channel subfamily J member 14 Kcnj14 0.0003 B w [59]
NM_032073 potassium voltage-gated channel, subfamily q, member 1 Kcnq1 0.0019 B w [59]
AI137995 sodium channel, voltage-gated, type iv, beta Scn4b 0.0087 B w [60]
NM_012618 s100 calcium-binding protein a4 S100a4 0.0066 E w [61]
NM_053587 s100 calcium binding protein a9 (calgranulin b) S100a9 0.0002 F w, z [62; 62]
X04280 calbindin 1 Calb1 0.0016 G w, z [63]
3. cAMP and adenylate cyclase cascade
M12672 guanine nucleotide binding protein, alpha inhibiting 2 Gnai2 0.0028 A y [64]
U39572 phosphatidylinositol 4-kinase, catalytic, alpha polypeptide Pik4ca 0.0096 A w [65]
NM_053926 phosphatidylinositol-4-phosphate 5-kinase, type ii, alpha Pip5k2a 0.0067 A w [65]
BF410504 g-protein-coupled receptor gpr34 GPR34 0.0000 D y [66]
NM_053456 phospholipase c-like 1 Plcl1 0.0000 D w [67]
BM386789 regulator of g-protein signaling 1 Rgs1 0.0071 E w [68]
BI281632 regulator of g-protein signalling 10 Rgs10 0.0008 F w [68]
NM_017142 adenylyl cyclase 8 Adcy8 0.0098 G y [35]
NM_134386 g protein-coupled receptor associated sorting protein 1 GASP1 0.0071 G w, y [69]
BF565001 phosphodiesterase 4d Pde4d 0.0053 G w [70]
AY043246 regulator of g-protein signaling 2 Rgs2 0.0003 G w [38]
NM_017214 regulator of g-protein signaling 4 Rgs4 0.0074 G w [38]
NM_080411 g protein-coupled receptor 83 Gpr83 0.0052 H y [66]
4. MAPK cascade
BG664160 mitogen-activated protein kinase kinase kinase kinase 3 Map4k3 0.0027 A w [34]
AF092450 mitogen activated protein kinase 8 interacting protein Mapk8i p 0.0001 A w [34]
NM_133545 protein tyrosine phosphatase 2e Ptpn21 0.0011 A w [71]
AI102620 mitogen activated protein kinase kinase kinase 1 Map3k1 0.0027 B w [33]
BI290864 mitogen activated protein kinase kinase kinase 3 Map3k3 0.0098 B w [33]
AJ271834 protein phosphatase 1b, magnesium dependent, beta 
isoform
Ppm1b 0.0000 B w [72]
BE113127 protein phosphatase 3, catalytic subunit, alpha isoform Ppp3ca 0.0029 B w [72]
AA924620 rab40b, member ras oncogene family Rab40b 0.0068 B y [73]
AI233712 protein phosphatase 1d magnesium-dependent, delta 
isoform
Ppm1d 0.0011 D y [72]
AI104546 protein tyrosine phosphatase 4a3 Ptp4a3 0.0067 E y [72]
NM_130403 protein phosphatase 1, regulatory (inhibitor) subunit 14a Ppp1r1 4a 0.0000 E y [72]BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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hyperalgesia-related memory. The enhanced hyperalgesia
is present even 28 days after the initial injection [7].
In this study we found alterations of gene expression that
lasted at least 28d and were quite different from transitory
changes observed 24h after injection. The genes altered at
24h include those involved in immune reaction and pro-
tein synthesis (Table 2), whereas long-lasting changes
observed 28 days after injection indicate different path-
ways, most notably those responsible for new synapse for-
mation (Table 3).
The observed short-term upregulation of the immune
response genes concurs with earlier reports that IL-6
[20,21] and TNF-a (tumor necrosis factor-a) [21] play an
important role in inflammatory pain. The upregulation of
these genes had previously been associated with the devel-
opment of neuropathic pain as well [22]. A similar result
has been found following nerve injury and spinal cord
injury (SCI). SCI induces a robust and significant increase
in mRNAs of inflammatory cytokines such as TNF-a, inter-
leukin-1β (IL-1β), and IL-6 at 1, 3, and 24 h post-injury
[23-25]. We do not know whether the changes in gene
expression are mediated by inflammation, pain, possible
injury to the nerve, or a combination thereof.
We observed significant changes in expression of several
key enzymes (3-alpha-hydroxysteroid dehydrogenase,
phospholipase a2, prostaglandin d2 synthase, and COX2)
involved in eicosanoid biosynthesis (Table 4, Arachidonic
acid cascade and mediators of inflammation). This cas-
cade is usually initiated by the activation of phospholi-
pase A2 and the release of arachidonic acid (AA) [26]. The
AA is subsequently transformed by cyclooxygenase (COX)
and lipoxygenase pathways to prostaglandins, thrombox-
ane, and leukotrienes, collectively termed eicosanoids.
Eicosanoid production is considerably increased during
inflammation and inflammation-induced pain, and COX
AI411122 rab1, member ras oncogene family Rab1 0.0013 H y [73]
BM384841 rab15, member ras onocogene family Rab15 0.0044 H y [73]
5. Growth factors and related proteins
NM_012513 brain derived neurotrophic factor BDNF 0.0067 B w, z [43] [42]
XM_231739 IGF2 binding protein 3 Igf2bp3 0.0091 D w [74]
NM_013104 IGF binding protein 6 Igfbp6 0.0020 E w [74]
BE102996 neurotrophic tyrosine kinase, receptor, type 2 Ntrk2 0.0042 E w [13]
U02315 neuregulin 1 Nrg1 0.0022 G w, z [75]
6. Arachidonic acid cascade and mediators of 
inflammation
NM_138547 3-alpha-hydroxysteroid dehydrogenase 0.0055 C w [76]
U03389 prostaglandin-endoperoxide synthase 2 cox2 0.0019 D w [77]
J04488 prostaglandin d2 synthase Ptgds 0.0017 E w [78]
NM_017020 interleukin 6 receptor Il6ra 0.0030 F w [76]
AA851740 interleukin 6 signal transducer Il6st 0.0025 F w [76]
NM_133551 phospholipase a2, group 4a Pla2g4a 0.0024 F w [79]
AA893169 tissue inhibitor of metalloproteinase 3 Timp3 0.0060 F w [9]
7. Others
NM_012823 annexin a3 Anxa3 0.0026 A w,z [14]
BI281979 microtubule-associated proteins 1b Map1lc 3b 0.0076 A y, z [15]
AB011679 tubulin, beta 5 Tubb5 0.0019 A y [17]
NM_023974 synaptoporin Synpr 0.0009 B y, z [16]
NM_012551 early growth response 1 Egr1 0.0037 B w [29]
BI294912 proteasome subunit, alpha type 3 Psma3 0.0020 D w [80]
BI283657 chaperonin subunit 4 (delta) Cct4 0.0001 F y [18]
BG372598 neural cell adhesion molecule 1 Ncam1 0.0045 F w,z [81]
NM_012755 fyn proto-oncogene Fyn 0.0010 E w [19]
For cluster description see Result and Figure 3.
Selection criteria:
w – involved in pain-related pathways.
y – interact with or regulate protein involved in pain perception.
z- expression level is altered in different model of pain.
Table 4: Genes differentially expressed 24h or 28d following carrageenan injection and known to be involved in pain. (Continued)BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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is the major target for nonsteroidal antiinflammatory
drugs (NSAIDs). It is possible that activation of eicosa-
noids by inflammation/pain causes lasting changes in
gene expression. NMDA receptors, which are prominently
involved in activity-dependent synaptic plasticity and
tonic pain [27], could mediate the upregulation of inflam-
matory factors. Inflammation-induced NMDAR activa-
tion involves phosphorylation of the NR1 and NR2B
subunits in the spinal dorsal horn by fyn proto-oncogene
[28]. The downstream changes in Egr1, MAPK, and AC
expression (see Table 4) can be also induced by activation
of the NMDA receptor. As an alternative, activation of the
neurotensin receptor can stimulate Egr1 expression and
MAP kinase pathways [29].
We do not know whether activation of eicosanoids and
MAP kinases is part of one inflammatory/pain pathway or
the former is the result of inflammation and the latter is
pain-induced. In any case, long-lasting changes in gene
expression are unlikely to be induced by ongoing inflam-
mation, since the majority of genes known to be involved
directly in the inflammatory response have a profile with
maximum changes at 24h and returning to control levels
28d following injection. No detectable changes of inflam-
matory cytokine genes, including those described above,
were found 28d after injection. However, initial inflam-
matory response may contribute to long-term changes in
gene expression and pain memory. A number of genes
altered in the 28d group are involved in inflammation-
induced potentiation of pain sensitivity. For example,
Comparison of microarray and Q-PCR results Figure 4
Comparison of microarray and Q-PCR results. Equal amounts of total RNA from each sample have been used for PCR 
amplification. The results were corrected for difference in PCR efficiency based on the dilution curves for each gene. Each gene 
expression was normalized to reference genes (sep15 and gtpbp4) to correct for possible error in RNA measurement. Data 
presented as expression relative to reference genes ± SEM. There were 8 control and 9 28d-group samples. p-value is unpaired 
t-test. Relative expression is presented as percentage of control.
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control 28d-group p-value Q PCR Array
lcn2 lipocalin 2 57.2 ± 2.5 51.3 ± 2.6 0.22 -10.3 -16.0
gabra6 GABA A receptor alpha 6 91.1 ± 13.5 90.7 ± 13.2 0.99 -0.4 -7.3
S100a4 S100 calcium-binding protein A4 69.8 ± 6.8 74.5 ± 7.5 0.66 6.6 31.6
ptgds prostaglandin D synthetase 75.4 ± 2.6 84.2 ± 3.2 0.03 11.6 10.9
insig1 insulin-induced gene 1 86.4 ± 6.2 110.9 ± 8.1 0.03 28.3 11.0
mmp14 matrix metalloproteinase 14 69.2 ± 9.1 89.8 ± 6.2 0.07 29.8 32.5
igf1 insulin-like growth factor 1 61.4 ± 7.4 87.5 ± 6.1 0.05 42.6 35.0
ca3 carbonic anhydrase 3 29.8 ± 13.3 108.0 ± 17.9 0.01 262.3 175.9BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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dynorphin [30,31], neuropeptide Y (NPY), and NPY (Y1)
receptor [32] are induced in the spinal cord by peripheral
inflammation. However, it is unknown whether activa-
tion of nociceptors is required.
Based on our expression data, carrageenan injection
affected at least two signal transduction pathways, MAPK
and cAMP/adenylyl cyclase (AC), known to regulate noci-
ceptive signal perception and transmission. Several iso-
forms of MAPK are involved in regulation of acute and
chronic pain both in neuron and glial cells [33,34]. cAMP
mediates many aspects of pain transmission within neu-
ronal cells. In particular, AC isoform 8 (AC8) that couples
NMDA receptor activation to cAMP signaling pathways in
neurons are important in the development of persistent
pain [35]. Activation of MAPK cascade might be mediated
by neurotensin receptor via Egr1, which is known to be
upregulated in response to persistent inflammatory pain
[29] and stimulates Erk1/2 phosphorylation [36]. It is
likely that an interaction between the glutamate pathway
and cAMP signaling is mediated by modulation of metab-
otropic glutamate receptor by RGS2 and RGS4 [37,38],
which were downregulated 24h after carrageenan injec-
tion (Table 4). Based solely on our data, we cannot tell
whether the trigger for long-term changes in gene expres-
sion is the initial inflammation or pain or their combina-
tion. It is also unlikely that all changes in gene expression
observed in the 28d group are related to formation and
maintenance of nociceptive memory. However, the prom-
inent group (Table 3) of differentially expressed genes
controls neuronal connectivity, synaptogenesis, and neu-
rogenesis. It is known that long-term memory and plastic-
ity in CNS depend on formation of new synapses that
require synthesis of proteins responsible for cell-to-cell
interaction–in particular cadherin-like protein. There is
also evidence that formation of new neurons is important
for memory formation and plasticity [39].
There is similarity in the development of long-term poten-
tiation (LTP), long-term memory, and pain. Research
indicates that central sensitization in the spinal cord has
the identical mechanism to LTP [40]. We have found that
a number of genes altered at 28d were also altered in the
hippocampus during LTP: brain-derived neurotrophic fac-
tor (BDNF), early growth response 1 (EGR1), CD9 anti-
gen (CD9), neuropeptide Y receptor Y5 (NPY5R), and
neuropeptide Y receptor (NPY1R) [41]. Genes such as
BDNF [13,42], NtrkB (BDNF receptor), Egr1 [29], neu-
ropeptide Y receptor, and neuregulin1 are also known to
be involved in inflammation-induced pain. For example,
BDNF, a known modulator of memory, was found to be
altered in rat pups one day after peripheral inflammation
induced by injection of Freund's complete adjuvant [43].
We do not believe, however, that pain memory and LTP
are identical phenomena but rather share some basic
mechanisms. They have different anatomical substrates,
and most alterations found in our study were not
observed in the hippocampus following memory forma-
tion. Based on our data, pain or inflammation or a com-
bination thereof induces dramatic changes in gene
expression. Most of these changes in gene expression sub-
side when inflammation disappears, while some of them
persist and even increase 28d later. Thus, part of the pain-
and inflammation-induced changes in gene expression
belong to pathway(s) that remain activated long after
inflammation and acute pain disappear. We can only
speculate which genes whose expression increased much
more at 28d than at 24h belong to these pathways. Addi-
tional experiments are needed to narrow down the list of
affected pathways. Based on the results of GO analysis,
proteins involved in synaptogenesis, cell-cell interaction,
and the formation of new neurons are overrepresented
among differentially expressed genes at 28d after carra-
geenan injection. Thus, we propose that pathways related
to synapse formation between newly generated neurons
are particularly important for "pain memory." The tenta-
tive nature of this conclusion depends on the exploratory
nature of our microarray data and analysis. The selection
of genes is based on a limited number of replicates and
multiple comparisons, which implies that a number of
genes may be false positives. We confirmed the differen-
tial expression for a few selected genes by PCR, but more
research is needed to complete verification of the microar-
ray data.
Conclusion
We have observed long-lasting changes in gene expression
following recovery from carrageenan-induced hyperalge-
sia. On the basis of these data, we propose that pathways
related to synapse formation are involved in the forma-
tion of pain memory.
Methods
The study was approved by the Harvard Medical Area
Standing Committee on Animals, Harvard Medical
School. Experiments were performed on male Sprague-
Dawley rats weighing 250–300 g that were housed with a
12-h light-dark cycle and food and water available ad libi-
tum.
Gene expression in the lumbar part of the spinal cord was
compared in three groups of rats: 28d after carrageenan
injection, 24h after carrageenan injection, and a control
group without injection.
Inflammation was induced by injection (26-gauge nee-
dle) of 0.1 ml of 2% carrageenan (Sigma Chemical Co., St.
Louis, MO) in the plantar surface of the hind paw under
halothane (2%) anesthesia. The rat paw volume was
measured by a plethysmometer (Paw Volume Meter; UgoBMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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Basile). The general procedure for measuring changes in
behavioral responses for microarray experiments was as
follows: For several days after arrival, rats were placed in
the testing environment, and during the two days preced-
ing the experiment, pressure threshold and hind paw vol-
umes were measured. On the experimental day, basal
values were determined twice with a 30-min interval; the
average value of two readings was used as a baseline. The
rats were assigned randomly (blocked randomization) to
one of three groups. Carrageenan was injected into the
right hind paw, and the rat was decapitated 24h or 28d
after injection. Paw volume was measured on both sides
2h, 4h, 24h, and 28d after each of the carrageenan injec-
tions. We assumed that pain-related memory is most
likely mediated by altered gene expression both in ipsilat-
eral and contralateral parts of the lumbar enlargement of
the spinal cord. In this study we have limited the measure-
ment of gene expression to the ipsilateral portion that is
most affected by carrageenan injection.
RNA isolation and Affymetrix GeneChip processing
The spinal cord was removed under hydraulic pressure
with 10-ml syringe with saline [44], and the lumbar
enlargement was dissected into ipsi- and contralateral
parts and frozen. Tissues were kept at -80°C until RNA
isolation.
Total RNA was isolated by quickly homogenizing the tis-
sue at high speed in Trizol (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions. The concen-
tration of total RNA was measured by UV spectrophotom-
etry, and RNA quality was confirmed by electrophoresis in
1% agarose gel and Agilent bioanalyzer (Agilent Technol-
ogies, Inc, Santa Clara CA). Only those samples that had
a 260/280 ratio more than 1.9 and had no signs of degra-
dation based on agarose electrophoresis were used for
analysis. The RNA samples were stored at -80°C.
Gene expression analyses were performed with the
Affymetrix Rat Genome 230 v.2 chip (Affymetrix, Santa
Clara, CA), which contains ~31,000 probe sets including
~17,000 annotated rat genes. For each chip, RNA from the
spinal cord of 3 rats was pooled to minimize interindivid-
ual variability. Pooled spinal cord RNA from the control,
24h, and 28d groups was hybridized in triplicate to the
Affymetrix 230 rat microarray, so that 9 animals were used
per treatment group. The labeling, hybridization, and
scanning were done through the NIH Neuroscience
Microarray Consortium at Affymetrix GeneChip Resource,
W. M. Keck Facility, Yale University School of Medicine,
according to Affymetrix protocol using recommended
equipment. The DNA chips were scanned by confocal
scanner. Digitized image data were processed the MAS
software (version 5.0) from Affymetrix. The expression
data reported in this paper have been deposited in the
National Center for Biotechnology Information Gene
Omnibus database.
Microarray Data Analysis
The resulting microarray data that passed quality control
tests were imported into the Rosetta Resolver system for
gene expression data analysis (Rosetta Biosoftware, Kirk-
land, WA). While it was imported, the microarray data
were subjected to background correction, intrachip nor-
malization, and the Rosetta Resolver system Affymetrix
GeneChip error model. The intensity profiles that are gen-
erated were used to build ratios with Rosetta Resolver
Ratio Builder. Briefly, the first step in data analysis
includes validation of each probe set based on empirical
error distribution and removal of the probe pairs that are
beyond three standard deviations from the mean. Probe-
level data were used to increase robustness by calculating
the averages. The expression values for individual profiles
were combined using an error-weighted average in a trans-
formed space, and the error of the result was adjusted cor-
respondingly. All profiles belonging to one single
experiment are normalized together. We have used global
normalization based on weighted average. The Ratio
Builder was used calculate ratio probabilities for the dif-
ferential expression among the control, 24h, and 28d
groups. More detailed information on the Rosetta
Resolver system Affymetix GeneChip error model, error-
weighted statistical model, and ratio building error model
can be found at Rosetta Resolver web site and in publica-
tions of Hughes et al. [45,46]. As a result of analysis, genes
were assigned p-values reflecting differences between the
control and injected groups. The p-values were used to
select genes for further clustering and functional classifica-
tion. Thus, the analysis of data was based on the combina-
tion of two procedures: Resolver error model and self-
organizing map (SOM) clustering complemented by func-
tional classification using DAVID [47]. We have used Affy
chip background since more specific list of gene related to
spinal cord expression is not available. SOM was applied
by the weighted pair-group method with centered average
and Pearson correlation implemented in the program
xCluster (kindly provided by Gavin Sherlock, Stanford
University). The differentially expressed genes were clus-
tered according to their expression in 24h and 28d groups.
Statistical differences within cluster were evaluated with
one way ANOVA followed by Scheffe test. At the next step,
the same genes differentially expressed at 28d and 24h
were functionally classified by gene ontology. We also
clustered genes known to be involved in inflammation
using SOM. In order to organize selected genes according
to the intracellular pathways involved, we used a context-
based information search and graphical tools (Gene-
Sphere, Malden, MA).BMC Neuroscience 2008, 9:32 http://www.biomedcentral.com/1471-2202/9/32
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The selection of genes known to be involved in pain per-
ception (Table 3) was based on gene ontology and a con-
text-based information search of PubMed-indexed
publications using the following criteria: a. protein
involved in pain-related pathways; b. gene expression
altered in different pain model; c. interaction with protein
involved in pain (Table 4).
RT-PCR Verification
Quantitative RT-PCR was used to verify the microarray
results for six randomly selected differentially expressed
genes and two genes that were not differentially expressed
on the gene array (negative control). RNA was extracted
from each animal as described above and cDNA was syn-
thesized using superscript reverse transcriptase (Invitro-
gen). PCR amplification used sybr green gene mix from
Biorad (Hercules, CA). Cycling parameters were 95°C for
10 min followed by 40 cycles of 95°C for 30 sec, Ta °C for
40 sec, and 72°C for 90 sec. Primers sequences are sum-
marized in Table 5. Amplification of each gene was
expressed as the amplification cycle at which its PCR prod-
uct was first detected (threshold cycle, CT). All samples
were run at the same plate. The relative quantification of
the target gene expression was performed according to the
comparative CT method (∆∆CT method). For each run,
the mean expression levels of target genes were normal-
ized to the mean expression levels of two endogenous ref-
erence genes (sep15 and gtpbp4). Serial dilution of
standard cDNA was used to correct for difference in
amplification efficiency. The "standard" cDNA for the
entire study was generated from a tissue homogenate,
which was obtained by pooling cDNA from all control
rats. PCR buffer and RNA were used as a negative control.
The resulting data were analyzed with unpaired t-test. The
Pearson correlation coefficient was used to compare fold
changes on gene arrays with those found on RT-PCR.
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